Search results
Showing 1231 to 1245 of 2011 results for nice guidelines
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
have produced treatment pathways bringing together NICE recommended treatment options from this guideline and relevant...
Home What NICE does Digital health...
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.
NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .
Providing an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.
View recommendations for TA121Show all sections
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.
of focal and generalised seizures since publication of the original NICE guideline on epilepsy in 2004 have not been...
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
Mersey Burns for calculating fluid resuscitation volume when managing burns (MIB58)
NICE has developed a medtech innovation briefing (MIB) on Mersey Burns for calculating fluid resuscitation volume when managing burns